MG
GOSS icon

Michael Gelband’s Gossamer Bio GOSS Stock Holding History

Michael Gelband’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105,056
Closed -$116K – 1654
2025
Q1 		$116K Buy
+105,056
New +$121K ﹤0.01% 1339
2024
Q2 		– Sell
-180,987
Closed -$214K – 1689
2024
Q1 		$214K Buy
+180,987
New +$199K ﹤0.01% 1335
2023
Q2 		– Sell
-163,769
Closed -$206K – 1996
2023
Q1 		$206K Buy
+163,769
New +$313K ﹤0.01% 1570
2022
Q4 		– Sell
-24,571
Closed -$294K – 1811
2022
Q3 		$294K Buy
+24,571
New +$305K ﹤0.01% 1530
2022
Q2 		– Sell
-17,865
Closed -$155K – 2127
2022
Q1 		$155K Buy
+17,865
New +$172K ﹤0.01% 1956
2021
Q4 		– Sell
-36,443
Closed -$458K – 2330
2021
Q3 		$458K Sell
36,443
-1,100
-3% -$10.1K 0.01% 1447
2021
Q2 		$305K Buy
+37,543
New +$326K ﹤0.01% 1730
2020
Q3 		– Sell
-44,317
Closed -$576K – 1924
2020
Q2 		$576K Buy
+44,317
New +$557K 0.02% 1005

Other funds holding GOSS

OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Michael Gelband's GOSS Position: Q2 2025 in Review

Michael Gelband sold out of Gossamer Bio (GOSS) in Q2 2025, closing a stake of 105,056 shares — an estimated $116K sold.

Michael Gelband first reported a position in GOSS in Q2 2020 and held it in 8 quarters. The position peaked at $576K in Q2 2020. 123 funds tracked by Wall St. Rank hold GOSS as of Q2 2025.

  • Michael Gelband reported no remaining Gossamer Bio position as of Q2 2025 after selling out during the quarter.
  • Michael Gelband sold 105,056 Gossamer Bio shares in Q2 2025, an estimated $116K.
  • Michael Gelband first reported a position in Gossamer Bio in Q2 2020 and held it in 8 quarters.
  • Michael Gelband's Gossamer Bio position peaked at $576K in Q2 2020.
  • 123 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.